南方财经 21世纪经济报道记者田静澳门报道 南方财经：实验室重组后在名称中加入"机制"二字，这是否标志着我国中医药研究的核心方向正在从传 统的"经验验证"向现代化的"机理阐释"进行战略转型？ 陈新：会的。现在推进中医药现代化、国际化和产业升级还有很多障碍，其中最大的障碍是中医药作用 机制说不清、道不明。很多人喜欢用中药治疗疾病或调理身体，但没有科学精准的方式来说明中药对身 体或疾病具体产生了什么作用，这严重妨碍了中医药的现代化、国际化和产业升级。 因此，我们想直接瞄准中医药最重要的科学方向，即中药的作用机制，尤其是免疫调节的作用机制，开 展深刻研究。比如人参用于抗肿瘤治疗，我们需要弄清楚它作用于肿瘤患者的哪些细胞或分子机制，以 及中药里哪些分子是发挥作用的物质基础。只有建立了这些科学证据，才能找到有效的质量控制方法， 实现精准的质量控制，判断中药质量是否合格，是否具有良好的临床疗效和安全性。 "中药为何有效？"这一困扰世人千年的问题，如今正迎来现代科学的集中解答。今年，澳门四所国家重 点实验室完成了重组整合。其中，原来的"中药质量全国重点实验室"重组为"中药机制与质量全国重点 实验室"。 近日，中药机制与质量 ...

中国发展网讯 记者明慧报道 11月15日上午，由中国当代医药杂志社和二十一世纪公益基金会主办，蒙 牛集团、扬子江药业集团、北京本草方源药业集团、百芝堂中医药集团、北京四方中药饮片有限公司等 单位协办，北京市大兴区卫生健康委员会、北京新融公益基金会等单位支持的第六届院士院长大会（简 称"两院论坛"）在北京市大兴区举行。中国中医药信息学会第四届理事会会长、国家中医药管理局原副 局长吴刚，中国科学院院士韩济生、陈润生、赵宇亮（线上），中国工程院院士蒋建东，第十三届全国 政协常委、国际核能院院士张勤，北京市大兴区委卫生健康工委书记、区卫生健康委主任牛祥君等来自 医药卫生界的行业领导、专家学者和来自全国各地的医疗机构负责人等320多位代表出席了15日上午举 行的开幕式。 开幕式由国家中医药管理局国际司原司长、中国医院协会副会长、中国中医科学院广安门医院原书记王 笑频主持，吴刚致辞。 在开幕式上，牛祥君在致辞中表示："今天我们有幸迎来医药健康领域的学术脊梁——各位院士，临床 实践一线的中坚力量——各位院长，以及深耕科研与产业赛道的专家、学者、企业家同仁。对大兴而 言，这既是一份至高荣誉，更是推动大兴卫生健康事业和医药健康 ...

Core Insights - The 2025 China Biotechnology Innovation Conference opened in Chengdu High-tech Zone, gathering over 1,000 experts and representatives from more than 50 well-known pharmaceutical companies to discuss the future of the global health industry [1][3] Event Overview - The conference, hosted by the China Biotechnology Development Center and organized by the Chengdu High-tech Zone Management Committee, spans three days and includes an opening ceremony, 14 sessions of sub-forums, technology achievement roadshows, and closed-door meetings [3] - The event features a comprehensive presentation of the latest dynamics, core challenges, and development opportunities in global biotechnology innovation through various formats [3] Key Reports and Presentations - The "2024 China Biopharmaceutical Park Competitiveness Ranking" was unveiled during the opening ceremony, with Chengdu High-tech Zone maintaining a leading position [3][5] - Notable presentations included: - A report by Academician Cao Xuetao on the strategic planning for innovative drug development over the next decade and the new era of biopharmaceuticals [3] - A report by Academician Chen Kaixian analyzing the development trends and innovation strategies in the chemical drug sector [4] - A report by Academician Chen Shilin discussing technological breakthroughs in the full industry chain development of traditional Chinese medicine [4] Specialized Sessions - The conference includes 14 specialized sessions covering topics such as AI-enabled innovative drug development, gene and cell therapy, modernization of traditional Chinese medicine, advanced industrial biotechnology, and disruptive technologies [4] Industry Reports - Four authoritative reports were released, including the "2025 China Life Sciences and Biotechnology Development Report" and the "2025 China Clinical Research Development Report," providing critical insights for industry development [5] - The "2025 China Biopharmaceutical Park Development Status Analysis Report" highlighted the competitive advantages of cities in biotechnology, with Chengdu High-tech Zone ranking alongside other leading innovation districts [5] New Initiatives - The "Global New Drug Discovery Center" was officially launched, aiming to integrate resources from over 3,000 biopharmaceutical companies in the region to create a comprehensive service system for drug discovery [6] - Chengdu High-tech Zone is focused on building a robust biopharmaceutical innovation ecosystem, enhancing collaboration between government, industry, academia, and research institutions to drive technological breakthroughs [6]

Core Viewpoint - The "Multi-target Cell Membrane Chromatography Intelligent Screening Analyzer" project, developed by Chengdu University of Traditional Chinese Medicine, Xi'an Jiaotong University, and Haineng Future Technology Group Co., Ltd., has been evaluated as a significant technological achievement that fills an international gap in the field [2][3][8]. Group 1: Project Evaluation - The evaluation was organized by the Sichuan Provincial Association for Science and Technology, with a panel of experts including academicians from various prestigious institutions [5][6]. - The expert panel unanimously agreed that the instrument is an international original, with advanced and reliable overall performance, and is a significant technological achievement [8]. Group 2: Instrument Features and Innovations - The instrument addresses the long-standing separation of "physical properties" and "activity" in traditional Chinese medicine research, providing critical support for establishing a research paradigm that aligns with the characteristics of traditional Chinese medicine [10]. - It is capable of accurately capturing key active components in complex systems, showcasing professional quality in its design, and has significant export potential and market appeal [10]. Group 3: Broader Implications - The achievement provides key technological support for explaining the scientific basis of traditional Chinese medicine compound preparations as innovative drugs, responding to major national regulatory needs [10]. - The project focuses on the collaborative action mechanism of "multi-component-multi-target" in traditional Chinese medicine, marking a significant leap towards intelligent analysis in the study of complex systems [12]. Group 4: Future Prospects - The instrument has vast application prospects not only in traditional Chinese medicine but also in natural product screening, drug development, quality control, and environmental testing [10]. - The successful development of the "Multi-target Cell Membrane Chromatography Intelligent Screening Analyzer" signifies a new phase in the intelligent analysis of complex systems, providing a robust technical support platform for modernizing traditional Chinese medicine and discovering innovative drugs [12][13].

Core Insights - The company Pianzaihuang has been awarded the "Most Investment Value Listed Company" at the 2025 Global Business Report Economic Forum, highlighting its long-term development potential recognized by the capital market [1] Group 1: Company Performance - Pianzaihuang has demonstrated excellence in corporate governance, value creation, strategic foresight, and social responsibility, which contributed to its recognition as a leading investment value company [1] - The company has a strong core product, Pianzaihuang, which has won the "West Pharmaceutical Gold Award" for liver and gallbladder medications, proving its effectiveness in preventing and treating acute and chronic liver damage [2] - Pianzaihuang's brand value has reached 43.739 billion yuan, ranking first in the "Hurun Brand List" for healthcare brands and leading the Chinese time-honored brand list [2] Group 2: Market Position and Strategy - The company has consistently ranked at the top of various industry lists, including the top 50 Chinese medicine companies and the top 100 pharmaceutical companies by main business income [2] - Pianzaihuang maintains a commitment to transparent operations and investor relations, having previously won the "Investor Relations Management Shareholder Return Award" [3] - The company aims to deepen the integration of production, education, and research, while exploring global market opportunities to enhance shareholder value and contribute to the modernization and internationalization of traditional Chinese medicine [3]

Core Points - The implementation of the "Private Economy Promotion Law" on May 20, 2025, is a significant milestone for the development of private enterprises in China, providing strong legal support for high-quality development in the private economy [1] - The law encourages private economic organizations to actively participate in technological innovation and the construction of a modern industrial system, which aligns with the goals of traditional Chinese medicine (TCM) enterprises [3][4] Company Insights - Fu Wang Guo Yi Tang, founded by Tang Huitian, is committed to continuous exploration in technological innovation, exemplified by their unique "Chinese Medicine Surgical Knife" system that aims to replace surgical interventions with specific herbal combinations [3][4] - The company emphasizes efficacy over excessive medical treatment and integrates traditional theories with modern pathology, addressing the talent bottleneck by collaborating with universities to train qualified TCM practitioners [4] - Fu Wang Guo Yi Tang has developed a series of health products focusing on "food and medicine homology," utilizing local medicinal materials while enhancing their health benefits [4] Industry Trends - The TCM industry is entering a golden era of high-quality development, driven by the "Healthy China 2030" initiative and advancements in digital technology [3] - Recent government policies, including the State Council's opinions on improving TCM quality, provide a clear development blueprint for the industry, with the "Private Economy Promotion Law" offering new opportunities and requirements for private enterprises [4][5] - The future of the TCM industry lies in leveraging modern technology to empower traditional wisdom, with Fu Wang Guo Yi Tang planning to enhance online sales channels and expand its reach through e-commerce partnerships [5]

Core Viewpoint - The article highlights the commitment of Panlong Pharmaceutical to traditional Chinese medicine and its social responsibility through various initiatives, including the establishment of medicinal herb planting bases and community health activities [1][5][8]. Group 1: Corporate Social Responsibility - Panlong Pharmaceutical organized a health consultation event in collaboration with Qinyuan Qinyao Traditional Chinese Medicine Museum, providing employees with access to expert medical advice, reflecting the company's "benevolent spirit" [1]. - The company has been actively involved in various charitable activities, demonstrating its commitment to social responsibility and sustainable development [1][5]. - In August 2023, Panlong Pharmaceutical participated in a "Golden Autumn Donation for Education" event, providing 250,000 yuan in scholarships to 85 students from low-income families [5][6]. Group 2: Medicinal Herb Planting Model - Panlong Pharmaceutical has established high-standard medicinal herb planting bases, including for honeysuckle and Schisandra, ensuring the quality of medicinal materials while contributing to rural revitalization [2][3]. - The company employs a "company + cooperative + farmer" model, which has significantly improved the income of participating farmers, with reports indicating that their overall earnings have more than doubled compared to independent farming [2][4]. Group 3: Modernization and Innovation - The company is leveraging IoT and smart monitoring technologies to enhance the cultivation and quality control of medicinal herbs, ensuring safety and traceability [3]. - Panlong Pharmaceutical is collaborating with universities to develop new varieties of traditional herbs, such as a high-yield, disease-resistant honeysuckle, which promises stable annual returns for farmers [3]. - The company is advancing its product development strategy, focusing on innovative drugs and modernizing traditional Chinese medicine, with several products in various stages of clinical development [8].

Core Viewpoint - Chengdu University of Traditional Chinese Medicine has announced procurement intentions for 19 items of laboratory equipment, with a total budget of 299 million yuan, aimed at enhancing its research capabilities and supporting the development of traditional Chinese medicine [2][3]. Procurement Overview - The procurement includes advanced instruments such as airborne hyperspectral imaging spectrometers, multifunctional circuit production instruments, flexible electronic rapid board-making instruments, multimodal brain function testing instruments, space electronic 3D printers, and fully electric inverted fluorescence microscopes, with an expected procurement date in October 2025 [3][4]. Instrument Descriptions - **Flexible Electronic Rapid Board-Making Instrument**: A desktop or miniaturized manufacturing device designed for the rapid, non-contact, and mask-free direct writing and forming of circuit patterns on flexible substrates, significantly shortening the cycle from design to physical product [4]. - **Airborne Hyperspectral Imaging Spectrometer**: An advanced remote sensing sensor mounted on aircraft or drones that captures spatial image information and continuous, fine spectral information simultaneously, enhancing applications in environmental monitoring, mineral exploration, agriculture, forestry, disaster assessment, and national defense [5]. Detailed Procurement List - The procurement list includes various teaching instruments aimed at upgrading existing equipment to support the integration of traditional Chinese medicine with modern technology, ensuring compliance with national and industry standards [7][9]. Research Platform Development - Chengdu University of Traditional Chinese Medicine has established a comprehensive research platform, including the Southwest Characteristic Traditional Chinese Medicine Resource National Key Laboratory, focusing on the preservation and innovation of traditional Chinese medicine resources [15][16]. Academic Achievements - The university has been recognized for its academic excellence, ranking among the top 1000 universities globally and holding several national key disciplines, which supports its role as a leader in traditional Chinese medicine education and research [14][16]. Future Prospects - The ongoing investment in advanced research equipment and platforms is expected to enhance the university's capabilities in traditional Chinese medicine research, contributing to the modernization and internationalization of the field [16].

Core Insights - The integration of traditional Chinese medicine (TCM) with artificial intelligence (AI) is being implemented in the coal mining sector to enhance the health management of workers [2][5][6] - A mobile TCM intelligent diagnostic center has been established, utilizing advanced smart devices to provide personalized health assessments for miners [2][5] Group 1: AI and TCM Integration - The intelligent diagnostic devices, including pulse and tongue diagnostic instruments, collect data and analyze it using a self-developed TCM model, resulting in detailed health reports and personalized treatment plans [2][5] - The initiative aims to address health risks faced by miners, such as joint pain and pneumoconiosis, by offering tailored health management solutions [2][5] Group 2: Technological Development - The development of the pulse diagnostic device faced challenges in accurately locating pulse characteristics, which was overcome through advanced visual algorithms [5] - A standardized color card for tongue diagnosis was created to ensure consistency in assessing tongue conditions, covering a full spectrum of TCM tongue diagnosis [5] Group 3: Future Plans and Policy Support - Plans are in place to establish "health cabins" that integrate smart devices into grassroots healthcare, aligning with the modernized service philosophy of TCM [5] - The Chinese government has issued guidelines to promote the digital and intelligent development of the TCM industry, emphasizing the importance of data-driven approaches [6]

Core Viewpoint - The recent controversy surrounding the Chinese medicine "Children's Intelligence Syrup" highlights public misunderstanding regarding its purpose, with many parents mistakenly believing it to be a supplement for increasing IQ, while experts clarify its actual function in improving attention and cognitive focus [1][3][5]. Group 1: Public Perception and Misunderstanding - The name "Children's Intelligence Syrup" has led to widespread misinterpretation among parents, associating "intelligence" with IQ enhancement rather than its intended use in improving attention and memory [3][5]. - Experts emphasize that "benefiting intelligence" in traditional Chinese medicine refers to enhancing cognitive function rather than increasing IQ levels, which is a modern misconception [3][5]. - Many parents request the syrup for their children with the hope of making them "smarter," which can lead to inappropriate use of the medication [3][5]. Group 2: Evidence and Clinical Practice - Since its introduction in the 1980s, "Children's Intelligence Syrup" has undergone numerous clinical studies that support its efficacy and safety, leading to its inclusion in authoritative medical guidelines [6][7]. - A clinical study published in December 2019 demonstrated that the syrup was more effective than Western medicine in treating symptoms of tic disorders, with fewer adverse reactions reported [6][7]. - The syrup has been recognized in updated clinical guidelines as a common choice for treating Attention Deficit Hyperactivity Disorder (ADHD), indicating a shift from empirical use to evidence-based recommendations [7][8]. Group 3: Quality Control and Regulatory Oversight - The quality and safety of "Children's Intelligence Syrup" are ensured through stringent quality standards and modern regulatory frameworks, which have been enhanced in the latest edition of the Chinese Pharmacopoeia [8][9]. - The National Medical Products Administration's adverse reaction monitoring system has reported a very low incidence of adverse reactions since the syrup's market introduction, indicating high overall safety [9][10]. - The leading manufacturer, Kewang Pharmaceutical, has implemented comprehensive quality management practices to ensure the syrup meets and exceeds industry standards [9][10]. Group 4: Rational Use and Parental Awareness - The effective use of "Children's Intelligence Syrup" depends on proper diagnosis and understanding of ADHD, as not all hyperactive children require medication [11][13]. - Experts stress the importance of adhering to prescribed dosages and treatment durations, as well as the need for professional evaluation before medication is administered [13][14]. - There is a call for improved public education regarding the appropriate use of the syrup, emphasizing the need for collaboration among healthcare providers, media, and educational institutions to enhance parental understanding [14][15]. Group 5: Broader Implications for Traditional Chinese Medicine - The discussion surrounding "Children's Intelligence Syrup" reflects broader societal challenges in understanding traditional Chinese medicine, balancing historical practices with modern scientific validation [15]. - This case serves as an example of how traditional remedies can be revitalized through contemporary scientific methods and regulatory frameworks, contributing to the modernization of Chinese medicine [15][16].